970 results match your criteria Neurotherapeutics [Journal]


Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.

Neurotherapeutics 2019 Apr 18. Epub 2019 Apr 18.

Department of Ophthalmology and Visual Sciences, Case Western Reserve University, 2085 Adelbert Rd., Room 303, Cleveland, OH, 44106, USA.

Cholesterol 24-hydroxylation is the major mechanism for cholesterol removal from the brain and the reaction catalyzed by cytochrome P450 46A1 (CYP46A1), a CNS-specific enzyme. This review describes CYP46A1 in the context of cholesterol homeostasis in the brain and summarizes available experimental data on CYP46A1 association with different neurologic diseases, including the mechanisms by which changes in the CYP46A1 activity in the brain could be beneficial for these diseases. The modulation of CYP46A1 activity by genetic and pharmacologic means is also presented along with a brief synopsis of the two clinical trials that evaluate CYP46A1 as a therapeutic target for Alzheimer's disease as well as Dravet and Lennox-Gastaut syndromes. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-019-00731-6
Publisher Site
http://dx.doi.org/10.1007/s13311-019-00731-6DOI Listing
April 2019
1 Read

Transcranial Magneto-Acoustic Stimulation Improves Neuroplasticity in Hippocampus of Parkinson's Disease Model Mice.

Neurotherapeutics 2019 Apr 16. Epub 2019 Apr 16.

College of Medicine, State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Nankai University, Tianjin, 300071, China.

In this study, we have, for the first time, demonstrated the beneficial effects of transcranial magneto-acoustic stimulation (TMAS), a technique based on focused ultrasound stimulation within static magnetic field, on the learning and memory abilities and neuroplasticity of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our results showed that chronic TMAS treatment (2 weeks) improved the outcome of Morris water maze, long-term potentiation (LTP), and dendritic spine densities in the dentate gyrus (DG) region of the hippocampus of PD model mice. To further investigate into the underlying mechanisms of these beneficial effects by TMAS, we quantified the proteins in the hippocampus that regulated neuroplasticity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00732-5DOI Listing
April 2019
2 Reads

Antisense Oligonucleotides for the Treatment of Inner Ear Dysfunction.

Neurotherapeutics 2019 Apr 10. Epub 2019 Apr 10.

Department of Special Education and Communication Disorders, University of Nebraska-Lincoln, 304 Barkley Memorial Center, Lincoln, NE, 68583, USA.

Antisense oligonucleotides (ASOs) have shown potential as therapeutic molecules for the treatment of inner ear dysfunction. The peripheral sensory organs responsible for both hearing and equilibrium are housed within the inner ear. Hearing loss and vestibular balance problems affect a large portion of the population and limited treatment options exist. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00729-0DOI Listing
April 2019
1 Read

Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients with Rheumatoid Arthritis?

Neurotherapeutics 2019 Apr 3. Epub 2019 Apr 3.

Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, 68 Jhonghua 3rd Road, Cianjin District, Kaohsiung City, 80145, Taiwan.

Disease-modifying anti-rheumatic drugs (DMARDs) can reduce inflammation and slow progression of rheumatoid arthritis (RA). It remains unknown what impact DMARDs may have on dementia, where inflammation also plays a critical role in pathogenesis. Patients without a prior history of dementia who were newly diagnosed with RA between 2000 and 2005 were identified from Taiwan's National Health Insurance Research Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00715-6DOI Listing
April 2019
2 Reads

Adhering to Ethical Benchmarks in Neurology Clinical Trials Using iPSCs.

Neurotherapeutics 2019 Mar 28. Epub 2019 Mar 28.

Department of Bioethics and Humanities, University of Washington School of Medicine, Seattle, WA, 98195-7120, USA.

We examine the ethics of using induced pluripotent stem cells (iPSCs) in cell transplantation treatment of neurologic diseases and the essential types of ethical benchmarks required in clinical trials in neurology using iPSCs, including embryonic pluripotent stem cells. We focus on two issues: (1) comparison and (2) criticism of the two types of neuro-hype (neuro-purism and neuro-essentialism). In order to ensure that the dialog on ethical benchmarks continues to develop in a manner that promotes trust with society and research subjects, concerns about the clinical use of pluripotent stem cells (particularly iPSCs) in neurology must be at the forefront of any ethics discussion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00728-1DOI Listing

Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease.

Neurotherapeutics 2019 Mar 26. Epub 2019 Mar 26.

Institute of Cognitive and Integrative Neuroscience of Aquitaine, CNRS UMR 5287, Allee Geoffroy St Hilaire, CS 50023, 33615, Pessac Cedex, France.

Huntington's disease (HD) is associated with sleep and circadian disturbances in addition to hallmark motor and cognitive impairments. Electrophysiological studies on HD mouse models have revealed an aberrant oscillatory activity at the beta frequency, during sleep, that is associated with HD pathology. Moreover, HD animal models display an abnormal sleep-wake cycle and sleep fragmentation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00726-3DOI Listing

Efficacy of Therapeutic Plasma Exchange in Patients with Severe Refractory Anti-NMDA Receptor Encephalitis.

Neurotherapeutics 2019 Mar 13. Epub 2019 Mar 13.

Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.

The objective of the present study was to assess the efficacy of therapeutic plasma exchange (TPE) in patients with severe refractory anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis. Patients with severe anti-NMDA receptor encephalitis who showed no improvement after steroids and/or intravenous immunoglobulin treatment for at least 10 days were enrolled. All patients received immunotherapy and were divided into a TPE group and a non-TPE group according to treatment received. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-019-00725-4
Publisher Site
http://dx.doi.org/10.1007/s13311-019-00725-4DOI Listing
March 2019
11 Reads

Nucleic Acid Vaccine Targeting Nogo-66 Receptor and Paired Immunoglobulin-Like Receptor B as an Immunotherapy Strategy for Spinal Cord Injury in Rats.

Neurotherapeutics 2019 Mar 6. Epub 2019 Mar 6.

State Key Laboratory of Trauma, Burns and Combined Injury, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, 400042, China.

Nogo-66 receptor (NgR) and paired immunoglobulin-like receptor B (PirB) are two common receptors of various myelin-associated inhibitors (MAIs) and, thus, play an important role in MAIs-induced inhibitory signalling of regeneration following spinal cord injury (SCI). Based on the concept of protective autoimmunity, vaccine approaches could induce the production of antibodies against inhibitors in myelin, such as using purified myelin, spinal cord homogenates, or MAIs receptor NgR, in order to block the inhibitory effects and promote functional recovery in SCI models. However, due to the complication of the molecules and the mechanisms involved in MAIs-mediated inhibitory signalling, these immunotherapy strategies have yielded inconsistent outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00718-3DOI Listing
March 2019
1 Read

Endovascular Stroke Therapy.

Authors:
Wade S Smith

Neurotherapeutics 2019 Mar 5. Epub 2019 Mar 5.

Department of Neurology, University of California, San Francisco, 505 Parnassus Ave, Box 0114, San Francisco, CA, 94143-0114, USA.

Ischemic stroke is a leading cause of death and disability throughout the world and is both preventable and treatable. This review focuses on the treatment of the most severe form of ischemic stroke, namely large-vessel ischemic stroke, using endovascular techniques. Such therapies were proven effective in 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00724-5DOI Listing

Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by H-NMR Spectroscopy.

Neurotherapeutics 2019 Feb 28. Epub 2019 Feb 28.

Multiple Sclerosis Centre, Department of Medical Sciences and Public Health, Binaghi Hospital, University of Cagliari, via Is Guadazzonis 2, 09126, Cagliari, Italy.

Metabolomic research has emerged as a promising approach to identify potential biomarkers in multiple sclerosis (MS). The aim of the present study was to determine the effect of interferon beta (IFN ß) on the metabolome of MS patients to explore possible biomarkers of disease activity and therapeutic response. Twenty-one MS patients starting IFN ß therapy (Rebif® 44 μg; s. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00721-8DOI Listing
February 2019

Neuroprotection of Fasting Mimicking Diet on MPTP-Induced Parkinson's Disease Mice via Gut Microbiota and Metabolites.

Neurotherapeutics 2019 Feb 27. Epub 2019 Feb 27.

Public Health Research Center at Jiangnan University, Wuxi Medical School, Jiangnan University, Wuxi, 214122, China.

Parkinson's disease (PD) is strongly associated with life style, especially dietary habits, which have gained attention as disease modifiers. Here, we report a fasting mimicking diet (FMD), fasting 3 days followed by 4 days of refeeding for three 1-week cycles, which accelerated the retention of motor function and attenuated the loss of dopaminergic neurons in the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrathydropyridine (MPTP)-induced PD mice. Levels of brain-derived neurotrophic factor (BDNF), known to promote the survival of dopaminergic neurons, were increased in PD mice after FMD, suggesting an involvement of BDNF in FMD-mediated neuroprotection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00719-2DOI Listing
February 2019
1 Read

Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation.

Neurotherapeutics 2019 Feb 27. Epub 2019 Feb 27.

Institute for Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Cientificas, Barcelona, 08034, Spain.

The development of neuroprotective therapies is a sought-after goal. By screening combinatorial chemical libraries using in vitro assays, we identified the small molecule BN201 that promotes the survival of cultured neural cells when subjected to oxidative stress or when deprived of trophic factors. Moreover, BN201 promotes neuronal differentiation, the differentiation of precursor cells to mature oligodendrocytes in vitro, and the myelination of new axons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00717-4DOI Listing
February 2019
2 Reads

Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats.

Neurotherapeutics 2019 Feb 22. Epub 2019 Feb 22.

Department of Clinical Pharmacology, University Hospital of Tuebingen, Auf der Morgenstelle 8, 72076, Tuebingen, Germany.

The contribution of the local angiotensin receptor system to neuroinflammation, impaired neurogenesis, and amyloid beta (Aβ) accumulation in Alzheimer's disease (AD) and in hypertension is consistent with the remarkable neuroprotection provided by angiotensin receptor blockers (ARBs) independent of their blood pressure-lowering effect. Considering the causal relationship between hypertension and AD and that targeting cerebrovascular pathology with ARBs does not necessarily require their systemic effects, we tested intranasal losartan in the rat model of chronic hypertension (spontaneously hypertensive stroke-prone rats, SHRSP). Intranasal losartan at a subdepressor dose decreased mortality, neuroinflammation, and perivascular content of Aβ by enhancing key players in its metabolism and clearance, including insulin-degrading enzyme, neprilysin, and transthyretin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00723-6DOI Listing
February 2019
4 Reads

Long-Term Follow-up in Patients with Spontaneous Intracerebral Hemorrhage Treated With or Without Surgical Intervention: a Large-Scale Retrospective Study.

Neurotherapeutics 2019 Feb 20. Epub 2019 Feb 20.

Department of Neurosurgery, China Medical University Hospital, 2 Hsueh-Shuh Road, Taichung, 40407, Taiwan.

Debates regarding the most beneficial medical or surgical procedures for patients with spontaneous intracerebral hemorrhage (sICH) are still ongoing. We aimed to evaluate the risk of subsequent vascular disease and mortality in patients with sICH treated with and without surgical intervention, in a large-scale Asian population. Patients hospitalized within 2000 to 2013 who were newly diagnosed with sICH were identified using the National Health Insurance Research Database of Taiwan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00722-7DOI Listing
February 2019
1 Read

High-Throughput Profiling of Circulating Antibody Signatures for Stroke Diagnosis Using Small Volumes of Whole Blood.

Neurotherapeutics 2019 Feb 19. Epub 2019 Feb 19.

Valtari Bio Incorporated, Morgantown, West Virginia, USA.

Accurate stroke recognition during triage can streamline care and afford patients earlier access to life-saving interventions. However, the tools currently available to clinicians for prehospital and early in-hospital identification of stroke are limited. The peripheral immune system is intricately involved in stroke pathology and thus may be targetable for the development of immunodiagnostics. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-019-00720-9
Publisher Site
http://dx.doi.org/10.1007/s13311-019-00720-9DOI Listing
February 2019
5 Reads

Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich's Ataxia Mouse Model.

Neurotherapeutics 2019 Feb 13. Epub 2019 Feb 13.

CIBER de Enfermedades Raras (CIBERER), Valencia, 46010, Spain.

Friedreich's ataxia (FRDA) is a neurodegenerative disorder caused by an unstable GAA repeat expansion within intron 1 of the FXN gene and characterized by peripheral neuropathy. A major feature of FRDA is frataxin deficiency with the loss of large sensory neurons of the dorsal root ganglia (DRG), namely proprioceptive neurons, undergoing dying-back neurodegeneration with progression to posterior columns of the spinal cord and cerebellar ataxia. We used isolated DRGs from a YG8R FRDA mouse model and C57BL/6J control mice for a proteomic study and a primary culture of sensory neurons from DRG to test novel pharmacological strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00706-zDOI Listing
February 2019
3 Reads

Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.

Neurotherapeutics 2019 Feb 13. Epub 2019 Feb 13.

Department of Nuclear Medicine, Seoul National University College of Medicine & SMG-SNU Boramae Medical Center, Dongjak-gu, Seoul, Republic of Korea.

This study tested the efficacy of the phosphodiesterase type III inhibitor cilostazol in Alzheimer's disease patients with white matter lesions treated with donepezil in comparison with donepezil monotherapy using fluorodeoxyglucose (F) positron-emission tomography (FDG PET). A 24-week, randomized, double-blind, placebo-controlled, parallel-group study was conducted. Thirty-six Alzheimer's disease patients with white matter lesions who received donepezil (n = 18 each in the cilostazol and placebo groups) were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00708-xDOI Listing
February 2019

Differentiation Between Guillain-Barré Syndrome and Acute-Onset Chronic Inflammatory Demyelinating Polyradiculoneuritis-a Prospective Follow-up Study Using Ultrasound and Neurophysiological Measurements.

Neurotherapeutics 2019 Feb 12. Epub 2019 Feb 12.

Center of Neurology, Tübingen University Hospital, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.

Differentiation of Guillain-Barré syndrome (GBS) and acute-onset chronic inflammatory demyelinating polyradiculoneuritis (CIDP) might be intricate in early stages. We compared electrodiagnostics (EDx) and nerve ultrasound (NUS) as tools for early distinction and follow-up. NUS and EDx have been performed at first visitation and after 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00716-5DOI Listing
February 2019
2 Reads

Nucleic Acid-Based Therapeutics for Parkinson's Disease.

Neurotherapeutics 2019 Feb 12. Epub 2019 Feb 12.

Robert Wood Johnson Medical School Institute for Neurological Therapeutics, and Department of Neurology, Rutgers Biomedical and Health Sciences, Piscataway, NJ, 08854, USA.

Parkinson's disease (PD) is a progressive neurodegenerative disorder that is diagnosed largely on clinical grounds due to characteristic motor manifestations that result from the loss of nigrostriatal dopaminergic neurons. While traditional pharmacological approaches to enhance dopamine levels, such as with L-dopa, can be very effective initially, the chronic use of this dopamine precursor is commonly plagued with motor response complications. Additionally, with advancing disease, non-motor manifestations emerge, including psychosis and dementia that compound patient disability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00714-7DOI Listing
February 2019
3 Reads

Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease.

Neurotherapeutics 2019 Feb 12. Epub 2019 Feb 12.

Basal Ganglia Pathophysiology Unit, Department of Experimental Medical Science, Lund University, BMC F11, Lund, Sweden.

Pridopidine is a small molecule in clinical development for the treatment of Huntington's disease. It was recently found to have high binding affinity to the sigma-1 receptor, a chaperone protein involved in cellular defense mechanisms and neuroplasticity. Here, we have evaluated the neuroprotective and neurorestorative effects of pridopidine in a unilateral 6-hydroxydopamine (6-OHDA) lesion model of parkinsonism in mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00699-9DOI Listing
February 2019

A Longitudinal Study of the Neurologic Safety of Acute Baclofen Use After Spinal Cord Injury.

Neurotherapeutics 2019 Feb 6. Epub 2019 Feb 6.

International Collaboration on Repair Discoveries (ICORD), University of British Columbia, 818 West 10th Avenue, Vancouver, British Columbia, V5Z 1M9, Canada.

The objective of our study was to determine whether treatment with baclofen is neurologically safe with respect to exposure during recovery from spinal cord injury. We performed a secondary longitudinal analysis of a cohort of adult patients with traumatic acute spinal cord injury. Cumulative baclofen dose was computed over the first 4 weeks following injury from concomitant medication information from a completed clinical trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00713-8DOI Listing
February 2019
3 Reads

Anti-Inflammatory and Neuroprotective Effects of DIPOPA (N,N-Diisopropyl-2-Oxopropanamide), an Ethyl Pyruvate Bioisoster, in the Postischemic Brain.

Neurotherapeutics 2019 Jan 24. Epub 2019 Jan 24.

Department of Anatomy, Inha University School of Medicine, Michuhol-gu Inharo 100, Inchon, 22202, Republic of Korea.

Ethyl pyruvate (EP) is a simple aliphatic ester of pyruvic acid and has been shown to have protective properties, which have been attributed to its anti-inflammatory, anti-oxidative, and anti-apoptotic functions. In an effort to develop better derivatives of EP, we previously synthesized DEOPA (N,N-diethyl-2-oxopropanamide, a novel isoster of EP) which has greater neuroprotective effects than EP, probably due to its anti-inflammatory and anti-excitotoxic effects. In the present study, we synthesized 3 DEOPA derivatives, in which its diethylamino group was substituted with diisopropylamino, dipropylamino, or diisobutylamino groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00711-wDOI Listing
January 2019

Stereoelectroencephalography Versus Subdural Electrodes for Localization of the Epileptogenic Zone: What Is the Evidence?

Neurotherapeutics 2019 Jan;16(1):59-66

Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, 15238, USA.

Accurate and safe localization of epileptic foci is the crux of surgical therapy for focal epilepsy. As an initial evaluation, patients with drug-resistant epilepsy often undergo evaluation by noninvasive methods to identify the epileptic focus (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00703-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361059PMC
January 2019
1 Read

A New Era for Surgical Neurotherapeutics.

Neurotherapeutics 2019 Jan;16(1):1-2

Center for the Neural Basis of Cognition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00709-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361065PMC
January 2019
2 Reads

Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond.

Neurotherapeutics 2019 Jan 14. Epub 2019 Jan 14.

Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Initiative for RNA Medicine, Boston, Massachusetts, 02115, USA.

Malignant brain tumors are rapidly progressive and often fatal owing to resistance to therapies and based on their complex biology, heterogeneity, and isolation from systemic circulation. Glioblastoma is the most common and most aggressive primary brain tumor, has high mortality, and affects both children and adults. Despite significant advances in understanding the pathology, multiple clinical trials employing various treatment strategies have failed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00702-3DOI Listing
January 2019

Herpes Viruses, Alzheimer's Disease, and Related Dementias: Unifying or Confusing Hypothesis?

Authors:
Avindra Nath

Neurotherapeutics 2019 Jan;16(1):180-181

Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bldg 10; Room 7C-103, 10 Center Drive, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00701-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361066PMC
January 2019

Nucleic Acid Therapies for Ischemic Stroke.

Neurotherapeutics 2019 Jan 11. Epub 2019 Jan 11.

Division of Neurocritical Care, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.

Stroke remains a leading cause of disability and death worldwide despite significant scientific and therapeutic advances. Therefore, there is a critical need to improve stroke prevention and treatment. In this review, we describe several examples that leverage nucleic acid therapeutics to improve stroke care through prevention, acute treatment, and recovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-019-00710-xDOI Listing
January 2019
3 Reads

Plasma Periostin and Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage.

Neurotherapeutics 2019 Jan 11. Epub 2019 Jan 11.

Department of Neurosurgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.

Delayed cerebral ischemia (DCI) is a serious complication of aneurysmal subarachnoid hemorrhage (SAH). Matricellular protein periostin (POSTN) has been found to be upregulated and linked with early brain injury after experimental SAH. The aim of the present study was to investigate the relationship between plasma POSTN levels and various clinical factors including serum levels of C-reactive protein (CRP), an inflammatory marker, in 109 consecutive SAH patients whose POSTN levels were measured at days 1-12 after aneurysmal obliteration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00707-yDOI Listing
January 2019
1 Read

Prostaglandin A1 Inhibits the Cognitive Decline of APP/PS1 Transgenic Mice via PPARγ/ABCA1-dependent Cholesterol Efflux Mechanisms.

Neurotherapeutics 2019 Jan 9. Epub 2019 Jan 9.

College of Life and Health Sciences, Northeastern University, No. 3-11. Wenhua Road, Shenyang, 110819, People's Republic of China.

Prostaglandins (PGs) are early and key contributors to chronic neurodegenerative diseases. As one important member of classical PGs, PGA1 has been reported to exert potential neuroprotective effects. However, the mechanisms remain unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00704-1DOI Listing
January 2019
1 Read

Herpes Infections and Dementia: Rebutting Alternative Fact.

Neurotherapeutics 2019 Jan;16(1):176-179

Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.

Recent commentary in Neurotherapeutics by Nath critically addresses the earlier report by Tzeng et al. that aggressive antiviral treatment (AVT) against herpes simplex virus (HSV) was associated with a later decrease in the incidence of Alzheimer's disease (AD). Nath raises issues that we respond to: we point out that (i) the treated group (probably with severe infection) is likely to harbor genetic risk alleles that predispose to both AD and HSV infection-the potential treatment bias cited by Nath would support (rather than challenge) the preventive effect of AVT; (ii) HSV is well known to establish persistent infection in the brain; and (iii) current AVT compounds used to combat herpes viruses are highly specific for this class of viruses. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00700-5
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00700-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361068PMC
January 2019
9 Reads

The Potential for a Speech Brain-Computer Interface Using Chronic Electrocorticography.

Neurotherapeutics 2019 Jan;16(1):144-165

Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

A brain-computer interface (BCI) is a technology that uses neural features to restore or augment the capabilities of its user. A BCI for speech would enable communication in real time via neural correlates of attempted or imagined speech. Such a technology would potentially restore communication and improve quality of life for locked-in patients and other patients with severe communication disorders. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00692-2
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00692-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361062PMC
January 2019
14 Reads

Toward Electrophysiology-Based Intelligent Adaptive Deep Brain Stimulation for Movement Disorders.

Neurotherapeutics 2019 Jan;16(1):105-118

Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

Deep brain stimulation (DBS) represents one of the major clinical breakthroughs in the age of translational neuroscience. In 1987, Benabid and colleagues demonstrated that high-frequency stimulation can mimic the effects of ablative neurosurgery in Parkinson's disease (PD), while offering two key advantages to previous procedures: adjustability and reversibility. Deep brain stimulation is now an established therapeutic approach that robustly alleviates symptoms in patients with movement disorders, such as Parkinson's disease, essential tremor, and dystonia, who present with inadequate or adverse responses to medication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00705-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361070PMC
January 2019
3 Reads

Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias.

Neurotherapeutics 2019 Jan 3. Epub 2019 Jan 3.

Department of Human Genetics, LUMC, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.

Autosomal dominant cerebellar ataxias (ADCAs) are a group of neurodegenerative disorders characterized by degeneration of the cerebellum and its connections. All ADCAs have progressive ataxia as their main clinical feature, frequently accompanied by dysarthria and oculomotor deficits. The most common spinocerebellar ataxias (SCAs) are 6 polyglutamine (polyQ) SCAs. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00696-y
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00696-yDOI Listing
January 2019
3 Reads

Spatial Training Ameliorates Long-Term Alzheimer's Disease-Like Pathological Deficits by Reducing NLRP3 Inflammasomes in PR5 Mice.

Neurotherapeutics 2018 Dec 17. Epub 2018 Dec 17.

Department of Neuropsychiatry, Affiliated Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.

Recent studies have suggested that cognitive training could delay memory loss in Alzheimer's disease (AD). However, whether and how cognitive training produces long-term benefits remains unclear. Here, 10-month-old PR5 mice were spatially trained in a water maze for 4 consecutive weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00698-wDOI Listing
December 2018
1 Read

Gene Therapy for Neurodegenerative Diseases.

Neurotherapeutics 2019 Jan;16(1):166-175

Brain Modulation Laboratory, Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, 15213, USA.

Gene therapy has the potential to provide therapeutic benefit to millions of people with neurodegenerative diseases through several means, including direct correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. Therapeutic efficacy is therefore dependent on knowledge of the disease pathogenesis and the required temporal and spatial specificity of gene expression. An additional critical challenge is achieving the most complete transduction of the target structure while avoiding leakage into neighboring regions or perivascular spaces. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00694-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361055PMC
January 2019

The Role of the Peripheral Nerve Surgeon in the Treatment of Pain.

Neurotherapeutics 2019 Jan;16(1):9-25

Division of Plastic and Reconstructive Surgery, Washington University in St. Louis, St. Louis, MO, USA.

Pain is a frequent cause of physician visits. Many physicians find these patients challenging because they often have complicated histories, emotional comorbidities, confusing examinations, difficult problems to fix, and the possibility of factitious complaints for attention or narcotic pain medications. As a result, many patients are lumped into the category of chronic, centralized pain and relegated to pain management. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00695-z
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00695-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361067PMC
January 2019
6 Reads

Tractography for Surgical Neuro-Oncology Planning: Towards a Gold Standard.

Neurotherapeutics 2019 Jan;16(1):36-51

Department of Neurosurgery, Stanford University, 300 Pasteur Drive, Palo Alto, CA, 94304, USA.

Magnetic resonance imaging tractography permits in vivo visualization of white matter structures. Aside from its academic value, tractography has been proven particularly useful to neurosurgeons for preoperative planning. Preoperative tractography permits both qualitative and quantitative analyses of tumor effects upon surrounding white matter, allowing the surgeon to specifically tailor their operative approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00697-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361069PMC
January 2019

Optimizing Trajectories for Cranial Laser Interstitial Thermal Therapy Using Computer-Assisted Planning: A Machine Learning Approach.

Neurotherapeutics 2019 Jan;16(1):182-191

Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, 33 Queen Square, London, WC1E 6BT, UK.

Laser interstitial thermal therapy (LITT) is an alternative to open surgery for drug-resistant focal mesial temporal lobe epilepsy (MTLE). Studies suggest maximal ablation of the mesial hippocampal head and amygdalohippocampal complex (AHC) improves seizure freedom rates while better neuropsychological outcomes are associated with sparing of the parahippocampal gyrus (PHG). Optimal trajectories avoid sulci and CSF cavities and maximize distance from vasculature. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00693-1
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00693-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361073PMC
January 2019
16 Reads

TET1 Overexpression Mitigates Neuropathic Pain Through Rescuing the Expression of μ-Opioid Receptor and Kv1.2 in the Primary Sensory Neurons.

Neurotherapeutics 2018 Dec 4. Epub 2018 Dec 4.

Department of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, 185 S. Orange Ave., MSB, E-661, Newark, NJ, 07103, USA.

Peripheral nerve injury downregulates the expression of the μ-opioid receptor (MOR) and voltage-gated potassium channel subunit Kv1.2 by increasing their DNA methylation in the dorsal root ganglion (DRG). Ten-eleven translocation methylcytosine dioxygenase 1 (TET1) causes DNA demethylation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00689-xDOI Listing
December 2018

Focused Ultrasound for Neuromodulation.

Authors:
David P Darrow

Neurotherapeutics 2019 Jan;16(1):88-99

Department of Neurosurgery, University of Minnesota, 420 Delaware St SE, MMC 96, Room D-429, Minneapolis, MN, 55455, USA.

For more than 70 years, the promise of noninvasive neuromodulation using focused ultrasound has been growing while diagnostic ultrasound established itself as a foundation of clinical imaging. Significant technical challenges have been overcome to allow transcranial focused ultrasound to deliver spatially restricted energy into the nervous system at a wide range of intensities. High-intensity focused ultrasound produces reliable permanent lesions within the brain, and low-intensity focused ultrasound has been reported to both excite and inhibit neural activity reversibly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00691-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361056PMC
January 2019
14 Reads

Behavioral and Cognitive Improvement Induced by Novel Imidazoline I Receptor Ligands in Female SAMP8 Mice.

Neurotherapeutics 2018 Nov 20. Epub 2018 Nov 20.

Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, Av. Joan XXIII, 27-31, 08028, Barcelona, Spain.

As populations increase their life expectancy, age-related neurodegenerative disorders such as Alzheimer's disease have become more common. I-Imidazoline receptors (I-IR) are widely distributed in the central nervous system, and dysregulation of I-IR in patients with neurodegenerative diseases has been reported, suggesting their implication in cognitive impairment. This evidence indicates that high-affinity selective I-IR ligands potentially contribute to the delay of neurodegeneration. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00681-5
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00681-5DOI Listing
November 2018
10 Reads

The Evolution of Selective Dorsal Rhizotomy for the Management of Spasticity.

Neurotherapeutics 2019 Jan;16(1):3-8

Division of Neurosurgery, Grootte Schuur Hospital, OMB H53, University of Cape Town, Observatory, Cape Town, South Africa.

Selective dorsal rhizotomy is a key technique in the surgical management of spasticity in patients with cerebral palsy. The technique evolved from the late 1800s when pioneers like Dana and Abbe performed dorsal rhizotomy in their treatment of refractory pain. These surgeons noted a reduction in muscle tone associated with the operation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00690-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361072PMC
January 2019
20 Reads

Myopathy: Recent Progress, Current Therapies, and Future Directions.

Neurotherapeutics 2018 10;15(4):837-839

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00688-y
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00688-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277290PMC
October 2018
19 Reads

Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease.

Neurotherapeutics 2018 10;15(4):966-975

Genetics and Genome Biology Program, Hospital for Sick Children, Toronto, ON, M5G 0A4, Canada.

Dynamin 2 (DNM2) belongs to a family of large GTPases that are well known for mediating membrane fission by oligomerizing at the neck of membrane invaginations. Autosomal dominant mutations in the ubiquitously expressed DNM2 cause 2 discrete neuromuscular diseases: autosomal dominant centronuclear myopathy (ADCNM) and dominant intermediate Charcot-Marie-Tooth neuropathy (CMT). CNM and CMT mutations may affect DNM2 in distinct manners: CNM mutations may cause protein hyperactivity with elevated GTPase and fission activities, while CMT mutations could impair DNM2 lipid binding and activity. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00686-0
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00686-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277281PMC
October 2018
13 Reads

Correction to: The Therapy of Congenital Myasthenic Syndromes.

Authors:
Andrew G Engel

Neurotherapeutics 2019 Jan;16(1):244

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

The third paragraph in the left column of page 256 of the article pertaining to the treatment of congenital choline acetyl transferase (ChAT) deficiency states that "Because apneic attacks occur suddenly in infants and children, the parents should be provided with an inflatable rescue bag." Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00672-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361064PMC
January 2019
1 Read

Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy.

Authors:
Perry B Shieh

Neurotherapeutics 2018 10;15(4):840-848

Department of Neurology, University of California, Los Angeles, 300 Medical Plaza, Suite B-200, Los Angeles, CA, 90095, USA.

Duchenne muscular dystrophy (DMD) is a progressive X-linked degenerative muscle disease due to mutations in the DMD gene. Genetic confirmation has become standard in recent years. Improvements in the standard of care for DMD have led to improved survival. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00687-z
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00687-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277306PMC
October 2018
22 Reads

Ryanodine Receptor 1-Related Myopathies: Diagnostic and Therapeutic Approaches.

Neurotherapeutics 2018 10;15(4):885-899

Neuromuscular Symptoms Unit, National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, USA.

Ryanodine receptor type 1-related myopathies (RYR1-RM) are the most common class of congenital myopathies. Historically, RYR1-RM classification and diagnosis have been guided by histopathologic findings on muscle biopsy. Main histological subtypes of RYR1-RM include central core disease, multiminicore disease, core-rod myopathy, centronuclear myopathy, and congenital fiber-type disproportion. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00677-1
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00677-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277304PMC
October 2018
8 Reads

Diagnosis and Treatment of Mitochondrial Myopathies.

Neurotherapeutics 2018 10;15(4):943-953

Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.

Mitochondrial myopathies are progressive muscle conditions caused primarily by the impairment of oxidative phosphorylation (OXPHOS) in the mitochondria. This causes a deficit in energy production in the form of adenosine triphosphate (ATP), particularly in skeletal muscle. The diagnosis of mitochondrial myopathy is reliant on the combination of numerous techniques including traditional histochemical, immunohistochemical, and biochemical testing combined with the fast-emerging molecular genetic techniques, namely next-generation sequencing (NGS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-00674-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277287PMC
October 2018
1 Read

Applications of Focused Ultrasound in Cerebrovascular Diseases and Brain Tumors.

Neurotherapeutics 2019 Jan;16(1):67-87

Focused Ultrasound Foundation, Charlottesville, Virginia, USA.

Oncology and cerebrovascular disease constitute two of the most common diseases afflicting the central nervous system. Standard of treatment of these pathologies is based on multidisciplinary approaches encompassing combination of interventional procedures such as open and endovascular surgeries, drugs (chemotherapies, anti-coagulants, anti-platelet therapies, thrombolytics), and radiation therapies. In this context, therapeutic ultrasound could represent a novel diagnostic/therapeutic in the armamentarium of the surgeon to treat these diseases. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00683-3
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00683-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361053PMC
January 2019
29 Reads

Myopathies Related to Glycogen Metabolism Disorders.

Neurotherapeutics 2018 10;15(4):915-927

Division of Neuromuscular & Neurometabolic Disorders, Departments of Pediatrics and Medicine, McMaster University, Hamilton Health Sciences Centre, Rm 2H26, Hamilton, ON, L8S 4L8, Canada.

Most of the glycogen metabolism disorders that affect skeletal muscle involve enzymes in glycogenolysis (myophosphorylase (PYGM), glycogen debranching enzyme (AGL), phosphorylase b kinase (PHKB)) and glycolysis (phosphofructokinase (PFK), phosphoglycerate mutase (PGAM2), aldolase A (ALDOA), β-enolase (ENO3)); however, 3 involve glycogen synthesis (glycogenin-1 (GYG1), glycogen synthase (GSE), and branching enzyme (GBE1)). Many present with exercise-induced cramps and rhabdomyolysis with higher-intensity exercise (i.e. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00684-2
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00684-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277299PMC
October 2018
24 Reads